Navigation Links
Upsher-Smith Laboratories Announces Expansion of Voluntary Nationwide Recall
Date:2/18/2011

MAPLE GROVE, Minn., Feb. 18, 2011 /PRNewswire/ -- Upsher-Smith Laboratories, Inc., of Maple Grove, Minnesota is voluntarily expanding its previously announced recall of Jantoven® Warfarin Sodium, USP, 3 mg Tablets to include additional products that were packaged on the same packaging line between May 17, 2010 and November 17, 2010.  The company is initiating the recall as a precautionary measure after a single bottle labeled as Jantoven® Warfarin Sodium, USP, 3 mg Tablets was found by a retail pharmacy to contain tablets at a higher, 10 mg strength.

At Upsher-Smith, patient safety is of foremost concern.  The substitution of warfarin, or any other product, may lead to a change in the therapeutic effect of the intended drug.Consistent, continuous dosing of any product is necessary for optimal care for many ill patients.  Patients should check with their health care provider regarding the appropriateness of their current therapy prior to making any change.  

The expanded recall includes the following products:ProductBatch NumberExpiration DateProduct IdentificationAmantadine 100 mg (100-ct bottles)

284166

Aug-12

Peach; imprinted AMT, 832Amantadine 100 mg (100-ct bottles)

280603

Jul-12

Peach; imprinted AMT, 832Amantadine 100 mg (100-ct bottles)

283797

Jul-12

Peach; imprinted AMT, 832Amlodipine 5 mg (90-ct bottles)

280564

May-12

White; scored; imprinted ALP, 5, 832Amlodipine 5 mg (90-ct bottles)

282661

Aug-12

White; scored; imprinted ALP, 5, 832Androxy 10 mg (100-ct bottles)

283336

Sep-12

Green; scored; imprinted 86, 832Baclofen 10 mg (90-ct bottles)

284651

Sep-12

White; scored; imprinted BAC, 10, 832Baclofen 10 mg (90-ct bottles)

282346

Aug-12

White; scored; imprinted BAC, 10, 832Baclofen 10 mg (100-ct bottles)

281664

Aug-12

White; scored; imprinted BAC, 10, 832Bethanechol 5 mg (100-ct bottles)

282255

Aug-12

White; scored; imprinted BCL, 5, 832Bethanechol 10 mg (100-ct bottles)

280569

Jun-12

White; scored; imprinted BCL, 10, 832Bethanechol 25 mg (100-ct bottles)

280567

Jun-12

Yellow; scored; imprinted BCL, 25, 832Jantoven 1 mg (100-ct bottles)

280617

Mar-12

Pink; scored; imprinted WRF, 1, 832Jantoven 1 mg (100-ct bottles)

282872

Jul-12

Pink; scored; imprinted WRF, 1, 832Jantoven 2 mg (100-ct bottles)

280598

Jun-12

Lavender; scored; imprinted WRF, 2, 832Jantoven 2.5 mg (100-ct bottles)

281667

Jul-12

Green; scored; imprinted WRF, 2 ½, 832Jantoven 3 mg (100-ct bottles)

280612

Jun-12

Tan; scored; imprinted WRF, 3, 832Jantoven 3 mg (100-ct bottles)

284081

Sep-12

Tan; scored; imprinted WRF, 3, 832Jantoven 4 mg (100-ct bottles)

283334

Jul-12

Blue; scored; imprinted WRF, 4, 832Jantoven 5 mg (100-ct bottles)

280581

Jun-12

Peach; scored; imprinted WRF, 5, 832Jantoven 5 mg (100-ct bottles)

283340

Jul-12

Peach; scored; imprinted WRF, 5, 832Jantoven 5 mg (100-ct bottles)

283459

Sep-12

Peach; scored; imprinted WRF, 5, 832Jantoven 5 mg (100-ct bottles)

283455

Jun-12

Peach; scored; imprinted WRF, 5, 832Jantoven 6 mg (100-ct bottles)

282277

Jun-12

Teal; scored; imprinted WRF, 6, 832Jantoven 6 mg (100-ct bottles)

284079

Sep-12

Teal; scored; imprinted WRF, 6, 832Jantoven 7.5 mg (100-ct bottles)

280614

Aug-12

Yellow; scored; imprinted WRF, 7 ½,

832Jantoven 10 mg (100-ct bottles)

283342

Aug-12

White; scored; imprinted WRF, 10, 832Jantoven 10 mg (100-ct bottles)

282917

Feb-12

White; scored; imprinted WRF, 10, 832Oxybutynin 5 mg (100-ct bottles)

283368

Jul-13

White; scored; imprinted 38, 832Upsher-Smith Laboratories is working cooperatively with the U.S. Food and Drug Administration to implement a nationwide recall as quickly and efficiently as possible.

The products affected were distributed to wholesalers, retail chains and independent pharmacies throughout the United States. The company is notifying its pharmacy customers and wholesalers, and arranging for the return of all recalled products.  These products were packaged at the Upsher-Smith plant in Plymouth, Minnesota.

Consumers and pharmacists can call 1-877-492-4791 for more information and to access product details, Monday-Friday between 8:00 a.m. and 5:00 p.m. (EST).

Any adverse reactions may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Online:

www.fda.gov/MedWatch/report.htmRegular:

Use postage-paid, pre addressed Form FDA 3500 available at: www.fda.gov/MedWatch/getforms.htm.  Mail to address on the pre-addressed form.Fax:

1-800-FDA-0178About Upsher-SmithUpsher-Smith Laboratories, Inc., founded in 1919, is a privately held pharmaceutical company that develops, manufactures and markets prescription and over-the-counter products.  Upsher-Smith's product portfolio focuses in the areas of women's health, dermatology, cardiology, and CNS diseases. Upsher-Smith is headquartered in Maple Grove, Minn. For more information, visit www.upsher-smith.com.


'/>"/>
SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Upsher-Smith Introduces Nexa™ Select With More Plant-Based DHA Than Any Other Once-Daily Single Gel Capsule Rx Prenatal Vitamin
2. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
3. Novo Nordisk Inc. Announces Exclusive Agreement With Upsher-Smith Laboratories, Inc. to Market Vagifem® 10 mcg
4. Upsher-Smith Laboratories Adds ITI-111 (Nasal Midazolam) to CNS Development Pipeline
5. Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
6. Upsher-Smith Introduces New Formulation of PreNexa® Prenatal Vitamins
7. Upsher-Smith Announces New Formulation of PreNexa(R) Prenatal Vitamins
8. Upsher-Smith Announces Milestone in Development of CNS Strategy
9. New Data: Cholesterol Management Analysis of Upsher-Smiths Slo-Niacin(R) Tablets in Combination with Lipitor(R)
10. Announcement - Clontech Laboratories, Inc. Releases the Tet-Express™ Inducible Expression System
11. Reportlinker Adds The U.S. Medical Laboratories Industry - 10th Edition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
(Date:10/10/2017)... EXTON, Pa. , Oct. 10, 2017   ... leader in innovative solutions for injectable drug administration, today ... of West,s ID Adapter for improving the intradermal administration ... the Fourth Skin Vaccination Summit in May 2017 by ... Team Lead, Polio Department, World Health Organization (WHO), and ...
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Leading pediatric oncology ... in Washington, D.C., for the 49th Congress of the International Society of Paediatric ... President of the Center for Cancer and Blood Disorders at Children’s National, ...
Breaking Medicine News(10 mins):